Helicobacter pylori, asthma and allergy
| Autor: | Amedeo Amedei, Gaia Codolo, Gianfranco Del Prete, Marina de Bernard, Paola Mazzi, Giorgio Berton, Mario Milco D'Elios, Giuseppe Zanotti |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Microbiology (medical)
Allergy Helper-Inducer T-Lymphocytes Immunology Population chemokines Inflammation Immunoglobulin E Microbiology Neutrophil Activation Helicobacter Infections Atopy Mice Bacterial Proteins Hypersensitivity medicine Animals Humans Immunology and Allergy Eosinophilia education Interleukin 5 education.field_of_study immune modulation Helicobacter pylori biology business.industry T-Lymphocytes Helper-Inducer General Medicine allergy biology.organism_classification medicine.disease Asthma Chemokines Cytokines Immune modulation asthma cytokines Infectious Diseases biology.protein medicine.symptom business |
| Zdroj: | FEMS Immunology & Medical Microbiology. 56:1-8 |
| ISSN: | 1574-695X 0928-8244 |
| DOI: | 10.1111/j.1574-695x.2009.00537.x |
| Popis: | Bronchial asthma and allergic diseases are orchestrated by T-cells producing T-helper type 2 (Th2) cytokines, such as interleukin-4 (IL-4) and IL-5, and are inhibited by Th1 responses. Helicobacter pylori has chronically infected the human population for c. 100,000 years and preferentially elicits a Th1 mucosal immune response with the production of interferon-gamma and IL-12. Among several bacterial factors, the neutrophil-activating protein of H. pylori (HP-NAP) not only plays a key role in driving Th1 inflammation but it is also able to inhibit Th2 responses in vitro and in vivo in allergic bronchial asthma, in humans and mice. Both systemic and mucosal administrations of HP-NAP are successful in reducing eosinophilia, immunoglobulin E and systemic Th2 cytokines at the bronchial level. Thus, these results identify HP-NAP as a candidate for novel strategies for the prevention and treatment of allergic diseases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text